Managing Recurrent Yeast Infections (RVVC)
At a Glance
Recurrent yeast infections should be confirmed with a fungal culture during an active flare before long-term treatment. Depending on the yeast species and reproductive status, treatment may include six-month fluconazole, boric acid, ibrexafungerp, or oteseconazole under medical supervision.
Living with Recurrent Vulvovaginal Candidiasis (RVVC) is more than just a physical challenge; it can be an exhausting emotional and psychological journey [1]. RVVC definitions vary by guideline—the CDC defines it as three or more symptomatic episodes in less than one year, while other authorities use four or more episodes in a 12-month period [2][3]. For many women, this translates to a cycle of chronic pain, reduced sexual satisfaction, and a significant burden on their mental health and daily quality of life [4][5][6].
The Necessity of Diagnostic Proof
If your symptoms keep returning, the most important step is to stop self-treating and seek a definitive diagnosis. It is easy to mistake other conditions for a yeast infection. In one specialist clinic study, 27% of patients referred for RVVC did not actually have the condition; they were instead dealing with issues like vulval eczema, dry skin, or vulvodynia [7]. Furthermore, 60% of women who did have confirmed RVVC also had a second, separate condition contributing to their symptoms [7].
Before starting long-term treatment, your doctor should obtain a sample during an active flare-up and perform a fungal culture [8]. This test identifies the specific species of yeast. However, a culture alone does not prove the yeast is resistant. If a confirmed infection fails appropriate therapy, susceptibility testing should be performed [9][10].
The Standard Six-Month Regimen
For appropriate, clinician-confirmed cases, the traditional “gold standard” for managing RVVC caused by susceptible yeast is a long-term course of oral fluconazole. This approach involves two phases:
- Induction Phase: You first clear the active infection. A common studied regimen is 150 mg of fluconazole taken three times, spaced 72 hours apart (e.g., on days 1, 4, and 7) [11].
- Maintenance Phase: Once symptoms are gone, you take a “suppressive” dose of 150 mg of fluconazole once a week for six months [12][13].
While this regimen controls symptoms for many people while they are on the medication, it is not a permanent cure for everyone. Relapse is common; one retrospective study found that 80.9% of women (among questionnaire respondents) experienced a return of symptoms after stopping the weekly therapy [13]. Long-term use requires clinician supervision to monitor for medication interactions, rare liver injury, and QT-related risks, and can sometimes lead the yeast to develop resistance [14].
Targeted Treatment: Boric Acid
If your culture shows a non-albicans species like Candida glabrata, which is often naturally resistant to fluconazole, your doctor may suggest vaginal boric acid [15].
- Regimen: Regimens vary by guideline. The CDC guidance for recurrent non-albicans VVC uses 600 mg vaginally once daily for three weeks [2]. Some other sources use 600 mg once or twice daily for 14 days to clear an active infection [16].
- Maintenance: Some experts suggest using it twice weekly as a maintenance therapy, but this evidence is limited and off-label [17].
- Safety Warning: Boric acid is fatal if swallowed [18]. It must only be used vaginally. Keep it safely stored away from children and pets. It is also strictly avoided during pregnancy because it may harm the developing fetus [19][17].
Newer Oral Options for RVVC
Two newer oral medications have been developed specifically to address the limitations of older treatments.
Ibrexafungerp
This medication kills yeast by targeting its cell wall differently than azoles do [20]. For RVVC, it is dosed as 300 mg twice in one day, repeated once every four weeks for six months [21]. In clinical trials, about 70.8% of women remained free of proven recurrence at the end of the 24-week treatment period [21].
- Warning: It is contraindicated in pregnancy and should not be used if you are trying to conceive [22].
Oteseconazole (Vivjoa)
Oteseconazole is designed to be highly specific to fungal enzymes, which helps it last longer in the body with fewer side effects [23]. The FDA-approved schedules include loading doses followed by weekly dosing over a specified period [24].
- Strict Reproductive Warning: Oteseconazole has an extremely long half-life. Because of potential risks to a fetus, it is FDA-approved only for females who are not of reproductive potential [24]. This generally refers to post-menopausal women or those with permanent infertility procedures like a hysterectomy, bilateral oophorectomy, or bilateral salpingectomy (a simple tubal ligation may not automatically qualify). A prescriber must verify eligibility.
| Treatment | Regimen Frequency | Best For | Key Concern |
|---|---|---|---|
| Fluconazole | Once weekly (6 mos) | C. albicans | High relapse after stopping |
| Boric Acid | Clinician-directed | Non-albicans yeast | Toxic if swallowed; avoid in pregnancy |
| Ibrexafungerp | One day per month (6 mos) | Resistant cases | GI side effects; avoid in pregnancy |
| Oteseconazole | See FDA label | Chronic RVVC | Females of non-reproductive potential only |
Managing RVVC requires patience. If you fail a supervised suppressive plan, or if tests are repeatedly negative despite persistent pain, request a referral to a gynecology, infectious disease, or vulvar-specialist team.
Common questions in this guide
What counts as recurrent vulvovaginal candidiasis?
How should recurrent yeast infections be confirmed?
What is the usual fluconazole schedule for RVVC?
When might boric acid be used for recurrent yeast infections?
Are ibrexafungerp and oteseconazole options for RVVC?
Can recurrent yeast infections return after six months of treatment?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
About testing
Should a fungal culture be taken during a flare-up to check which yeast is involved?
Treatment options
What would a long-term oral fluconazole plan involve, and how is it supervised?
Specialist referral
Should I ask for a specialist referral if symptoms persist after a supervised plan?
Get notified when new evidence is published on vulvovaginal candidiasis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (24)
- 1
Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis.
Zhu YX, Li T, Fan SR, et al.
Health and quality of life outcomes 2016; (14()):65 doi:10.1186/s12955-016-0470-2.
PMID: 27129474 - 2
Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
Nyirjesy P, Brookhart C, Lazenby G, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022; (74(Suppl_2)):S162-S168 doi:10.1093/cid/ciab1057.
PMID: 35416967 - 3
Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis.
Sobel JD, Donders G, Degenhardt T, et al.
NEJM evidence 2022; (1(8)):EVIDoa2100055 doi:10.1056/EVIDoa2100055.
PMID: 38319878 - 4
Influence of recurrent vulvovaginal candidiasis on quality of life issues.
Fukazawa EI, Witkin SS, Robial R, et al.
Archives of gynecology and obstetrics 2019; (300(3)):647-650 doi:10.1007/s00404-019-05228-3.
PMID: 31270690 - 5
Association of sexual function and psychological symptoms including depression, anxiety and stress in women with recurrent vulvovaginal candidiasis
Moshfeghy Z, Tahari S, Janghorban R, et al.
Journal of the Turkish German Gynecological Association 2020; (21(2)):90-96 doi:10.4274/jtgga.galenos.2019.2019.0077.
PMID: 31640303 - 6
Lived experience of medical management in recurrent vulvovaginal candidiasis: a qualitative study of an uncertain journey.
Bradfield Strydom M, Walpola RL, McMillan S, et al.
BMC women's health 2022; (22(1)):384 doi:10.1186/s12905-022-01973-x.
PMID: 36123738 - 7
Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes.
Brown L, Chamula M, Weinberg S, et al.
Journal of fungi (Basel, Switzerland) 2022; (8(9)) doi:10.3390/jof8090924.
PMID: 36135648 - 8
Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis.
Neal CM, Martens MG
SAGE open medicine 2022; (10()):20503121221115201 doi:10.1177/20503121221115201.
PMID: 36105548 - 9
Non-albicans Candida and rare yeasts in vulvovaginal candidiasis: pathogen attribution, antifungal resistance, persistence, and species-informed management.
Yan Z, Cui Y, Li Y, et al.
Frontiers in microbiology 2026; (17()):1944046 doi:10.3389/fmicb.2026.1944046.
PMID: 42780976 - 10
Increasing rate of non-Candida albicans yeasts and fluconazole resistance in yeast isolates from women with recurrent vulvovaginal candidiasis in Leeds, United Kingdom.
Ratner JC, Wilson J, Roberts K, et al.
Sexually transmitted infections 2025; (101(1)):21-26 doi:10.1136/sextrans-2024-056186.
PMID: 39379166 - 11
Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Martens MG, Maximos B, Degenhardt T, et al.
American journal of obstetrics and gynecology 2022; (227(6)):880.e1-880.e11 doi:10.1016/j.ajog.2022.07.023.
PMID: 35863457 - 12
Recurrent vulvovaginal candidiasis: A review of guideline recommendations.
Matheson A, Mazza D
The Australian & New Zealand journal of obstetrics & gynaecology 2017; (57(2)):139-145 doi:10.1111/ajo.12592.
PMID: 28299777 - 13
Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.
Collins LM, Moore R, Sobel JD
Journal of lower genital tract disease 2020; (24(1)):48-52 doi:10.1097/LGT.0000000000000496.
PMID: 31860575 - 14
A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates.
Sobel JD, Sebastian S, Boikov DA
Mycoses 2023; (66(7)):563-565 doi:10.1111/myc.13582.
PMID: 36866967 - 15
Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center.
Powell AM, Gracely E, Nyirjesy P
Journal of lower genital tract disease 2016; (20(1)):85-9 doi:10.1097/LGT.0000000000000126.
PMID: 26083330 - 16
Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
Mendling W, Brasch J, Cornely OA, et al.
Mycoses 2015; (58 Suppl 1()):1-15 doi:10.1111/myc.12292.
PMID: 25711406 - 17
Topical Treatment of Recurrent Vulvovaginal Candidiasis: An Expert Consensus.
Phillips NA, Bachmann G, Haefner H, et al.
Women's health reports (New Rochelle, N.Y.) 2022; (3(1)):38-42 doi:10.1089/whr.2021.0065.
PMID: 35136875 - 18
Boric Acid, a Lewis Acid With Unique and Unusual Properties: Formulation Implications.
Lopalco A, Lopedota AA, Laquintana V, et al.
Journal of pharmaceutical sciences 2020; (109(8)):2375-2386 doi:10.1016/j.xphs.2020.04.015.
PMID: 32353453 - 19
Data on Safety of Intravaginal Boric Acid Use in Pregnant and Nonpregnant Women: A Narrative Review.
Mittelstaedt R, Kretz A, Levine M, et al.
Sexually transmitted diseases 2021; (48(12)):e241-e247 doi:10.1097/OLQ.0000000000001562.
PMID: 34561373 - 20
Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Phillips NA, Rocktashel M, Merjanian L
Drug design, development and therapy 2023; (17()):363-367 doi:10.2147/DDDT.S339349.
PMID: 36785761 - 21
A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis.
Goje O, Azie NE, Angulo DA, et al.
American journal of obstetrics and gynecology 2025; (233(6)):617.e1-617.e18 doi:10.1016/j.ajog.2025.07.040.
PMID: 40752754 - 22
Ibrexafungerp: A new triterpenoid antifungal.
Sucher AJ, Thai A, Tran C, et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2022; (79(24)):2208-2221 doi:10.1093/ajhp/zxac256.
PMID: 36083109 - 23
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.
Ordaya EE, Clement J, Vergidis P
Mycopathologia 2023; (188(6)):937-948 doi:10.1007/s11046-023-00759-5.
PMID: 37470902 - 24
Oteseconazole: First Approval.
Hoy SM
Drugs 2022; (82(9)):1017-1023 doi:10.1007/s40265-022-01734-y.
PMID: 35713845
This page is for informational purposes only and does not constitute medical advice. A clinician should confirm recurrent vulvovaginal candidiasis and supervise treatment, especially when pregnancy or medication safety is a concern.